| Nov 15 |
COSCIENS Biopharma Third Quarter 2024 Earnings: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)
|
| Nov 12 |
COSCIENS Biopharma reports Q3 results
|
| Nov 12 |
COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
|
| Oct 8 |
COSCIENS Biopharma Announces Change to Board of Directors
|
| Oct 1 |
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
|
| Sep 23 |
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
|
| Aug 27 |
COSCIENS Biopharma crashes on trial setback for lead asset
|
| Aug 27 |
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
|
| Aug 13 |
COSCIENS Biopharma GAAP EPS of -$0.64, revenue of $2.3M
|
| Aug 13 |
COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
|
